Latest filing published 17 Feb 2026 for Fusion Antibodies plc.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +165.3%Entry £0.03 · Close at T+365 £0.09
- +14.7%Entry £0.05 · Close at T+365 £0.05
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Simon Douglas: trading record in brief
All filings by Simon Douglas on record concern Fusion Antibodies plc. Over a trading history stretching from 4 December 2023 to 17 February 2026, the count stands at 3 filings.
The open-market record is one-sided, with 2 purchases worth €12k and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay.
Most recently, on 17 February 2026, the filings show a transaction in Fusion Antibodies plc. The most recent open-market purchase was published on 22 July 2024, 839 days ago. Half of the filings or more reach the RNS (LSE) feed on the day of the trade. Under the UK Market Abuse Regulation, managers have three business days to notify their trades. These figures are compiled from regulatory filings published by RNS (LSE). They describe what insiders did and are not a recommendation.
Companies and markets linked to Simon Douglas
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 200,000 sharesOutside a trading venueISIN GB00BDQZGK16RNS:625c20a4-5316-4800-9ba1-a770f1f5960e
- 150,000 shares@ £0.032149.5% of flowXLON, London Stock ExchangeISIN GB00BDQZGK16RNS:5275959Canonical exit: 20 Oct 2024 (T+90)
- 100,565 shares@ £0.049650.5% of flowXLON, London Stock ExchangeISIN GB00BDQZGK16RNS:4991240-0Canonical exit: 3 Mar 2024 (T+90)
3 of 3 declarations